Literature DB >> 9253337

Panhypopituitarism as a model to study the metabolism of dehydroepiandrosterone (DHEA) in humans.

J Young1, B Couzinet, K Nahoul, S Brailly, P Chanson, E E Baulieu, G Schaison.   

Abstract

The physiological importance and therapeutical interest of dehydroepiandrosterone (DHEA) and its sulfate ester (DHEAS) are still controversial. Panhypopituitarism is characterized by the absence of secretion of adrenal and gonadal steroids and thus the production of their metabolites. The conversion of DHEA given orally into delta 5 derivatives, androgens, androgen metabolites, and estrogens was studied in ten patients with complete panhypopituitarism. Sex steroid therapy was withdrawn for at least 2 months. Each patient received, at 1-month intervals and in a random order, two single oral doses of DHEA (50 mg and 200 mg) and placebo. During each treatment, urine samples were collected for 24 h, and blood samples were drawn at hourly intervals for 8 h. In patients with pituitary deficiency, plasma DHEA and DHEAS were not detectable and increased, with the 50 mg dose, up to levels observed in young adults. The administration of 200 mg of DHEA induced an increase of both steroids to supraphysiological plasma levels. A small increase of delta 5-androstenediol was observed. In contrast, the increase of plasma delta 4-androstenedione was important and dose dependent. DHEA was also converted into the potent sex steroid testosterone (T). The administration of a 50 mg dose of DHEA restored plasma T to levels similar to those observed in young women. The 200 mg dose induced an important increase of plasma T, slightly below the levels observed in normal men. The increase of plasma dihydrotestosterone levels was small at both doses of DHEA, in contrast with the large conversion of DHEA into androsterone glucuronide and androstanediol glucuronide. Finally, DHEA administration induced a significant and dose dependent increase of plasma estrogens and particularly of estradiol. In conclusion, this short term study demonstrates that: 1) panhypopituitarism is a model of interest to study the metabolism of DHEA; 2) in the absence of pituitary hormones and of adrenal and gonadal steroids, DHEA given orally is mainly converted into delta 4 derivatives, which in turn are strongly metabolized into 5 alpha-3keto-reduced steroids; 3) a significant increase of sex active hormones was observed in plasma after 200 and even 50 mg of DHEA. Thus, biotransformation of DHEA into potent androgens and estrogens may explain several of the reported beneficial actions of this steroid in aging people.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9253337     DOI: 10.1210/jcem.82.8.4157

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  12 in total

1.  Prospective measurements of dehydroepiandrosterone sulfate in a cohort of elderly subjects: relationship to gender, subjective health, smoking habits, and 10-year mortality.

Authors:  L Mazat; S Lafont; C Berr; B Debuire; J F Tessier; J F Dartigues; E E Baulieu
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-26       Impact factor: 11.205

2.  Effects of dehydroepiandrosterone (DHEA) supplementation on hormonal, metabolic and behavioral status in patients with hypoadrenalism.

Authors:  R Libè; L Barbetta; C Dall'Asta; F Salvaggio; C Gala; P Beck-Peccoz; B Ambrosi
Journal:  J Endocrinol Invest       Date:  2004-09       Impact factor: 4.256

3.  DHEA-S levels in hypopituitaric patients with severe GH deficiency are strongly reduced across lifespan. Comparison with IGF-I levels before and during rhGH replacement.

Authors:  G Aimaretti; C Baffoni; M R Ambrosio; M Maccario; G Corneli; S Bellone; M Gasperi; E Degli Uberti; E Ghigo
Journal:  J Endocrinol Invest       Date:  2000-01       Impact factor: 4.256

Review 4.  Pregnenolone, dehydroepiandrosterone, and schizophrenia: alterations and clinical trials.

Authors:  Michael S Ritsner
Journal:  CNS Neurosci Ther       Date:  2010       Impact factor: 5.243

5.  Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial.

Authors:  Eleanor M Gurnell; Penelope J Hunt; Suzanne E Curran; Catherine L Conway; Eleanor M Pullenayegum; Felicia A Huppert; Juliet E Compston; Joseph Herbert; V Krishna K Chatterjee
Journal:  J Clin Endocrinol Metab       Date:  2007-11-13       Impact factor: 5.958

Review 6.  Might DHEA be considered a beneficial replacement therapy in the elderly?

Authors:  Alessandro D Genazzani; Chiara Lanzoni; Andrea R Genazzani
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 7.  Androgen replacement therapy in androgen-deficient women with hypopituitarism.

Authors:  Hong Zang; Susan R Davis
Journal:  Drugs       Date:  2008       Impact factor: 9.546

8.  Impact of transitional care on endocrine and anthropometric parameters in Prader-Willi syndrome.

Authors:  A C Paepegaey; M Coupaye; A Jaziri; F Ménesguen; B Dubern; M Polak; J M Oppert; M Tauber; G Pinto; C Poitou
Journal:  Endocr Connect       Date:  2018-04-17       Impact factor: 3.335

Review 9.  Hormonal and Metabolic Changes of Aging and the Influence of Lifestyle Modifications.

Authors:  Mark W Pataky; William F Young; K Sreekumaran Nair
Journal:  Mayo Clin Proc       Date:  2021-03       Impact factor: 7.616

10.  The use of hormones indicators in human saliva in diagnosing parodontitis in pregnant women.

Authors:  S I Dolomatov; W Zukow; I D Atmazhov; R Muszkieta; A Skaliy
Journal:  Indian J Hum Genet       Date:  2012-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.